Pancreatitis associated with incretin-based therapies

Diabetes Care

Volumn 36, Issue 4, 2013, Pages

  Iyer, Shridhar N ^a   Tanenberg, Robert J ^b   Mendez, Carlos E ^c   West, R Lee ^b   Drake III, Almond J ^b  

^a ALBANY MEDICAL CENTER   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c STRATTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SITAGLIPTIN;

DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG CONTRAINDICATION; DRUG LABELING; DRUG SAFETY; DRUG SUBSTITUTION; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PANCREATITIS; PEPTIDES; PYRAZINES; TRIAZOLES; VENOMS;

EID: 84875464034     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1987     Document Type: Letter

References (5)

1. Patel MB, Elmore LK, Edgerton LP, Whalin LM. Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. Am J Health Syst Pharm 2012;69:1044-1048
2. Violante R, Oliveira JHA, Yoon KH, et al. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet Med 2012;29:e417-e4244
3. U.S. Food and Drug Administration. Drugs: Information for healthcare professionals: exenatide (marketed as Byetta) [Internet], 2008. Available from http://www.fda.gov/Drugs/ DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm124713. htm. Accessed 16 September 2012
4. U.S. Food and Drug Administration. Safety: Sitagliptin (marketed as Januvia and Janumet) -acute pancreatitis [Internet], 2009. Available from http://www.fda.gov/ Safety/MedWatch/SafetyInformation/Safety AlertsforHumanMedicalProducts/ucm183800. htm. Accessed 16 September 16 2012
5. Iyer SN, Drake AJ, West RL, et al. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr Pract 2012;18:e10-e13